logo

Meet Vidhi Shanghvi, daughter of India's richest pharma tycoon, steering a Rs 3.95 lakh crore company

Time of India18-06-2025
Vidhi Shanghvi, daughter of India's pharma tycoon Dilip Shanghvi, is making headlines for her impressive role in Sun Pharma, one of India's biggest pharmaceutical companies. With a net worth of $25 billion, Dilip Shanghvi is India's richest pharma billionaire and among the top 100 richest people in the world. But now, all eyes are on his daughter Vidhi Shanghvi, who is slowly stepping into the limelight with her strong leadership and modern approach to business.
Who is Vidhi Shanghvi?
Vidhi Shanghvi is currently the Executive Director at Sun Pharma, a company founded by her father, Dilip Shanghvi in 1983. Sun Pharma started as a maker of psychiatric drugs and has grown to become India's most valuable pharma company, with a market capitalisation of ₹3.95 lakh crore. Vidhi was recently appointed as Whole-time Director for a five-year term, showing her growing influence within the company.
Educational Background of Vidhi Shanghvi
Following the footsteps of many billionaire heirs, Vidhi Shanghvi studied abroad to gain global exposure. She graduated from the prestigious Wharton School at the University of Pennsylvania, a top business school in the world. Her academic background has helped her bring fresh and innovative ideas to Sun Pharma, especially in areas like marketing and consumer healthcare.
Career Journey at Sun Pharma
Vidhi Shanghvi began her career at Sun Pharma in 2012 as a Brand Manager in the India Business division. Over the years, she has held several leadership positions. In 2014, she became the Marketing Head for one of the company's Cardiovascular Business Units. She led many successful marketing campaigns and was instrumental in improving business operations and initiating digital transformation projects.
Leading Sun Pharma's Consumer Healthcare and Distribution
In 2015, after the merger of Ranbaxy with Sun Pharma, Vidhi Shanghvi was made the Business Head of the company's Consumer Healthcare Division. Under her leadership, this division has grown rapidly. She has played a key role in boosting the presence of popular products like Revital H and Volini across retail stores, pharmacies, and online platforms in India.
Apart from Consumer Healthcare, Vidhi Shanghvi also leads India Distribution – a crucial part of Sun Pharma's value chain. Her efforts have helped improve supply efficiency and expand reach across the country.
Over 13 Years of Experience in Pharma Sector
With more than 13 years of professional experience, Vidhi Shanghvi has built expertise in various fields, including marketing, brand building, project and alliance management, and distribution. Her dynamic leadership style and strategic thinking have earned her recognition within the industry.
Vidhi Shanghvi's Passion for Mental Health
Beyond her corporate role at Sun Pharma, Vidhi Shanghvi is also deeply committed to mental health. She is the founder of Mann Talks, a not-for-profit mental health initiative. This platform provides free, holistic mental health solutions and encourages individuals to take charge of their mental well-being.
What is Dilip Shanghvi's Net Worth?
Dilip Shanghvi, founder of Sun Pharma, has an estimated net worth of $25.8 billion, according to Forbes. As of today, June 18, he is the 77th richest person in the world and remains one of the most successful entrepreneurs in India. His vision and leadership have shaped Sun Pharma into a global pharmaceutical giant.
Vidhi Shanghvi's Brother Also Plays a Key Role
Vidhi Shanghvi's brother, Aalok Shanghvi, is also part of the leadership at Sun Pharma. A few months ago, he was promoted to the position of Chief Operating Officer (COO), making it a truly family-led business.
Vidhi Shanghvi is clearly following in the footsteps of her father Dilip Shanghvi, but she is also building her own legacy at Sun Pharma. With a strong academic background, diverse industry experience, and a clear passion for healthcare and innovation, Vidhi Shanghvi is emerging as a powerful new-age leader in the Indian pharmaceutical sector.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sprays, pills, creams...ooh, aah, ouch? India's pain market is now a Rs 16,000 cr giant
Sprays, pills, creams...ooh, aah, ouch? India's pain market is now a Rs 16,000 cr giant

Economic Times

time2 days ago

  • Economic Times

Sprays, pills, creams...ooh, aah, ouch? India's pain market is now a Rs 16,000 cr giant

Synopsis India's pain relief market has exploded post-pandemic, doubling to nearly ₹16,000 crore in just five years. From gels and sprays to pills like Dolo and Zerodol, pain meds are now a daily fix for everything from gym soreness to chronic stress. The shift is lifestyle-driven and increasingly normalised, but experts warn against unchecked self-medication. As the over-the-counter space booms, driven by awareness and ease of access, the line between relief and risk is getting worryingly thin. Agencies Mumbai: Indians are increasingly popping over-the-counter pills, using sprays or rubbing in creams to soothe their aches and pains, adding more than a billion dollars to the pain management market over the past five years. The category is the biggest within the non-prescription segment, and has seen about five brands launched every week on average since the pandemic, industry executives said, citing Nielsen data. There were 1,552 brands -including Volini, Omnigel, Dolo and Saridon -to tackle the twinges in 2020; now, there are 2,771. Consumers are more attentive to alleviating any pain on a more immediate basis, said Shivam Puri, managing director at Cipla Health, which sells the biggest rubefacient brand, Omnigel. Rubefacient are gels and creams for topical application. "Rise of urbanisation and increase in chronic illnesses have led to the need for faster, more convenient formats that are accessible across platforms," said Puri. This is despite medical professionals advising caution on random use of painkillers. The pain relief category is often lifestyle-driven in urban markets, especially with gym and sports injuries. As a result, the market for analgesics (pain relief medication) and rubefacient more than doubled to ₹15,905 crore as of May this year, from ₹6,820 crore as of May 2020, growing at a compounded annual rate of 18%. This is three times faster than overall over-the-counter market growth, which rose at 6% CAGR to ₹80,000 crore. Analgesics account for 75% of the pain medication market and within analgesics, paracetamol is the biggest contributor, according to data from market researcher PharmaTrac. Covid has changed Indians' views on pain management, said Sandeep Verma, head for consumer health business for South Asia at Bayer Pharmaceuticals, which sells Saridon. 'A lot of Indians view taking pain relief medication as a sign of weakness or worry about becoming dependent on it. Covid made many of us more aware of how stress, exhaustion, and even mild but recurring pain can chip away at our wellbeing and productivity,' he said.'More people are starting to understand that living with untreated pain impacts their quality of life."Experts said pain management medications are also used to treat inflammation and adjacent issues, widening the need for the pills.'The analgesic segment that is dominated by paracetamols has been growing at a steady rate of 10%. This is because paracetamol medications are taken alongside other conditions that could include arthritis, any other bacterial or viral infection,' said Sheetal Sapale, vice president, commercial, at Kumar Sinha, consultant physician at Mumbai-based WeCare Wellness, said lifestyle-related problems — including rising stress levels, lack of sleep and increasing obesity — are reasons for increasing demand for pain medications.'Lack of physical exercise, increase in body weight leading to knee and joint pain, anxiety, depression are all causes of increase in body pain, headaches or migraine,' he said.'There is also an increase in people doing self-medication and several mandatory prescription drugs, strong painkillers and anti-inflammatory medications — that can have severe harmful effects, such as damage to the kidneys, if used over a prolonged period — are today available easily at chemist shops without prescriptions,' said top-selling drugs in the pain category are IPCA's Zerodol SP, Janssen's Ultracet, GSK's Calpol, Micro Lab's Dolo, Torrent's Chymoral Forte and Cipla's Ibugesic Plus. A majority of them are prescription pain is not the only category that people are self-medicating in since the pandemic. Skin creams, earlier prescribed by dermatologists, are drawing a consumer base, especially Gen Z products, which treat scalp and skin issues and form the second biggest category after pain, expanded 8% CAGR over the past five years and are now a ₹14,854 crore Prakash, partner and healthcare services industry leader at Grant Thornton, said, 'Over-the-counter as a segment has grown post-Covid because of more knowledge and information for categories including anti-allergic medications, skin creams, tear drops among others.'

Tariff delay sparks relief rally in Indian pharma stocks: Sudip Bandyopadhyay
Tariff delay sparks relief rally in Indian pharma stocks: Sudip Bandyopadhyay

Economic Times

time2 days ago

  • Economic Times

Tariff delay sparks relief rally in Indian pharma stocks: Sudip Bandyopadhyay

Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel "The uncertainty is not around demand or the price hike but the uncertainties are company specific. JSW Steel , we will definitely want to hear what is their strategy about Bhushan Steel, that is a huge problem which has been created in the recent past post the Supreme Court order and one needs to understand how that will get disentangled," says Sudip Bandyopadhyay , Group Chairman, Inditrade Capital Well, of course, what has changed significantly is the tariff announcement by President Trump. There was a sword hanging on pharma sector and at different levels different figures were being thrown around. But finally, when the announcement came, it talks about very high 200% or whatever but it is after two obviously people immediately started talking about the fact that probably it will never come because if something gets pushed back by two years obviously there is no threat of imminent tariff on pharma products, so that was a fantastic news for most Indian pharma companies because most of them or at least a lot of them have significant business in do manufacture in India and supply to US, so they would have been adversely affected by the tariff and since that is not happening, that was the point from where pharma actually we started seeing significant momentum in largecap and some midcap pharma companies. As far as overall pharma is concerned Sun Pharma does look good because some of the molecules which they were expected to commercialise a bit later in the year is getting preponed and the commercial launch is happening in US very-very soon and that kind of enthused the investors about Sun they have significant business in US as well as India and both the markets are expected to do good. The pricing pressure on generics is, of course, there but that has kind of reached a level where we have seen the course, Glenmark did a landmark deal and it is not only for Glenmark, for the entire Indian pharmaceutical industry this was a landmark deal with R&D getting established and getting properly valued by global pharma players, so this was definitely landmark and of course, Glenmark investors were rewarded and will be rewarded further I am sure in terms of dividend or other some kind of payouts, so that is as far as Glenmark and Sun Pharma is by and large Indian pharma can breathe a sigh of relief post the tariffs sword going away and it is back to business as usual and considering that most of the sectors are kind of still awaiting to know about the tariff and its implications, pharma is one sector where that has been taken care of. Hence, pharma is rallying, that is my it is definitely positive for the overall steel industry. We have to remember that globally also demand for steel is going up and naturally price hike in the domestic scenario is also expected. The uncertainty is not around demand or the price hike but the uncertainties are company specific. JSW Steel , we will definitely want to hear what is their strategy about Bhushan Steel, that is a huge problem which has been created in the recent past post the Supreme Court order and one needs to understand how that will get is very critical for JSW Steel at this stage. Of course, coking coal prices of the entire industry will be interesting to understands the trend and what the management commentary is for multiple companies not only JSW Steel because that is a very-very critical ingredient as far as steel making is and large, we believe that the industry margins would have improved in this current quarter for which results will come out. Top line depends on company specific like JSW Steel had a scheduled maintenance, so obviously the volume will be low, but the margin improvement will be visible.

Sun Pharma Share Price Live Updates: Sun Pharma's Stock Price Declines Below 100-Day EMA
Sun Pharma Share Price Live Updates: Sun Pharma's Stock Price Declines Below 100-Day EMA

Time of India

time2 days ago

  • Time of India

Sun Pharma Share Price Live Updates: Sun Pharma's Stock Price Declines Below 100-Day EMA

18 Jul 2025 | 09:35:27 AM IST Discover the Sun Pharma Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a top-performing stock. Keep track of Sun Pharma's latest details, including: Last traded price 1697.0, Market capitalization: 407215.13, Volume: 68878, Price-to-earnings ratio 37.26, Earnings per share 45.55. Our liveblog offers a holistic view of Sun Pharma by examining both fundamental and technical indicators. Stay ahead of market trends with breakingnews that can impact Sun Pharma's performance. Our market analysis and expert opinions provide valuable insights to guide your investment decisions. Join us on the Sun Pharma Stock Liveblog and stay informed in this dynamic market landscape. The data points are updated as on 09:35:27 AM IST, 18 Jul 2025 Show more

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store